First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomized MACRO2 TTD study
FI: 7,191
Type: Article
Collaboration
Year: 2018
Writers
Aranda, E; Garcia-Alfonso, P; Benavides, M; Ruiz, AS; Guillen-Ponce, C; Safont, MJ; Warden, J; Gomez, A; Lopez, R; Manzano, JL; Urena, MM; Tailor, J; Rivera, F; Gravalos, C; Garcia, T; Martin-Valades, JI; Falco, E; Navalon, M; Flores, EG; Tapiador, AMG; Munoz, AML; Barrajon, E; Reboredo, M; Teijido, PG; Viudez, A; Cardenas, N; Diaz-Rubio, E
Magazine
Title: EUROPEAN JOURNAL OF CANCER
Quartile
- Q1